LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma. (26th February 2014)

• Record Type: Journal Article
• Authors: Lossos, Chen; Bayraktar, Soley; Weinzierl, Elizabeth; Younes, Sheren F.; Hosein, Peter J.; Tibshirani, Robert J.; Sutton Posthumus, Jocelyn; DeAngelis, Lisa M.; Raizer, Jeffrey; Schiff, David; Abrey, Lauren; Natkunam, Yasodha; Lossos, Izidore S.
• Is Part Of: British journal of haematology. Volume 165:Number 5(2014:Jun.)
• Page Start: 640
• Page End: 648
• Publication Date: 2014-02-26
• Subjects: Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.12801
• Languages: English
• ISSNs: 0007-1048

Abstract

<abstract abstract-type="main" id="bjh12801-abs-0001"> <title>Summary</title> <p>Primary central nervous system lymphoma (PCNSL) is an aggressive sub‐variant of non‐Hodgkin lymphoma (NHL) with morphological similarities to diffuse large B‐cell lymphoma (DLBCL). While methotrexate (MTX)‐based therapies have improved patient survival, the disease remains incurable in most cases and its pathogenesis is poorly understood. We evaluated 69 cases of PCNSL for the expression of <italic>HGAL</italic> (also known as <italic>GCSAM</italic>), <italic>LMO2</italic> and <italic>BCL6</italic> – genes associated with DLBCL prognosis and pathobiology, and analysed their correlation to survival in 49 PCNSL patients receiving MTX‐based therapy. We demonstrate that PCNSL expresses LMO2, HGAL(also known as GCSAM) and BCL6 proteins in 52%, 65% and 56% of tumours, respectively. BCL6 protein expression was associated with longer progression‐free survival (<italic>P</italic> = 0·006) and overall survival (OS, <italic> P</italic> = 0·05), while expression of LMO2 protein was associated with longer OS (<italic>P</italic> = 0·027). Further research is needed to elucidate the function of <italic>BCL6</italic> and <italic>LMO2</italic> in PCNSL.</p> </abstract>